Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

PrE0113:A study to assess overall response rate by inducing an inflammatory phenotype in Metastatic BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with anti-PD-L1 Avelumab and Paclitaxel BRACELET-1 Study

Principal Investigator: Levine, Ellis G

An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2-Breast Cancer with an ESR1 Mutation

Principal Investigator: O'Connor, Tracey L

A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer

Principal Investigator: Gandhi, Shipra

An Open-label Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI5395 in Combination with Durvalumab in Subjects with Select Advanced Solid Tumors

Principal Investigator: Dy, Grace K

EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response

Principal Investigator: Levine, Ellis G

(A011202) A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 NI) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Principal Investigator: Levine, Ellis G

A phase 1/2 Study of in situ vaccination with tremelimumab and IV durvalumab (MEDI4736) plus the Toll-like receptor agonist PolyICLC in Subjects with Advanced, Measurable, Biopsy-accessible Cancers

Principal Investigator: Puzanov, Igor

A Phase 1 Study with Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Eribulin ORA (HM30181A + Eribulin) in Subjects with Solid Tumors (ATX-ERB-001)

Principal Investigator: Gandhi, Shipra

Exercise to Improve Health and Quality-of-life in Breast Cancer Survivors: A Feasibility Pilot Trial

Principal Investigator: O'Connor, Tracey L

Phase I Clinical Trial Assessing the Combination of Chemokine Modulation with Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Principal Investigator: Gandhi, Shipra

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Principal Investigator: Levine, Ellis G

NRG-BR004, "A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer," (NCT03199885)

Principal Investigator: Levine, Ellis G

A randomized phase II study to evaluate efficacy of TDM1with or without Palbociclib in the treatment of patients with metastatic HER2 positive breast cancer

Principal Investigator: Gandhi, Shipra

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)

Principal Investigator: Levine, Ellis G

Enhancing a home-based walking intervention among breast cancer survivors with rTMS: Feasibility and limited efficacy testing

Principal Investigator: Sheffer, Christine E

Exercise and Nutrition Intervention in Older Breast Cancer Survivors

Principal Investigator: O'Connor, Tracey L

(S1706) A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Principal Investigator: Fung-Kee-Fung, Simon